Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Wall Street Zen to Strong Sell

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by Wall Street Zen to a “strong sell” rating in a report released on Saturday.

Several other equities analysts also recently weighed in on TVRD. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. HC Wainwright initiated coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective on the stock. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research report on Tuesday, July 7th. Finally, Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $3.20 on Friday. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The company has a market capitalization of $30.02 million, a PE ratio of -1.03 and a beta of 0.39. The stock has a fifty day moving average of $3.04 and a two-hundred day moving average of $3.50.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, equities research analysts forecast that Tvardi Therapeutics will post -2.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TVRD. XTX Topco Ltd acquired a new position in Tvardi Therapeutics during the fourth quarter valued at approximately $55,000. Quadrature Capital Ltd acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter worth $90,000. Russell Investments Group Ltd. raised its stake in shares of Tvardi Therapeutics by 1,351.5% in the 4th quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after acquiring an additional 14,866 shares during the period. Squarepoint Ops LLC raised its stake in shares of Tvardi Therapeutics by 534.3% in the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after acquiring an additional 43,619 shares during the period. Finally, Arax Advisory Partners lifted its holdings in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after acquiring an additional 6,173 shares in the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.